KR20200018527A - Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate - Google Patents

Abstract

The present invention relates to a stable pharmaceutical composition containing omeprazole, an enantiomer or pharmaceutically acceptable salt thereof, and sodium hydrogen carbonate. Specifically, the present invention relates to a pharmaceutical composition having improved stability, which contains a low content of sodium hydrogen carbonate, has an excellent dissolution rate and bioavailability, and has reduced side effects caused by a high content of sodium hydrogen carbonate.

Description

Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate

The present invention relates to a stable pharmaceutical composition comprising omeprazole, an enantiomer or pharmaceutically acceptable salt thereof, and sodium hydrogen carbonate. In particular, it relates to a pharmaceutical composition comprising a low content of sodium hydrogen carbonate, having an excellent dissolution rate and bioavailability and having improved stability which reduces the side effects caused by high content of sodium hydrogen carbonate.

The chemical name of omeprazole is 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl-1H-benzimidazole. Omeprazole exists in two isomers, the R-isomer and the S-isomer. S-isomers are known to be superior to R-isomers in terms of therapeutic effects and side effects. The S-isomer is (S) -5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl) -methyl] sulfinyl-1H-benzimidazole and isomeprazole ( esomeprazole).

Eomeprazole is a representative proton pump inhibitor used in the treatment of indigestion, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. ; PPI).

It is well known in the art that omeprazoles, in particular esomeprazole, are susceptible to degradation or modification in acidic and neutral media, and more specifically, the degradation half-life of esomeprazole in aqueous solutions with a pH value of 3 or less is known to be less than 10 minutes. Thus, degradation of esomeprazole is promoted by acidic compounds and is also affected by moisture, heat, organic solvents and light.

Therefore, there has been a lot of demands for a stable esomeprazole formulation, and in order to solve the stability problem, Korean Patent No. 384960 prepares a pellet containing magnesium salt of esomeprazole, and then enteric coating and then formulated into a tablet by adding an excipient A method is disclosed. The formulation prepared by the method described above is currently being sold under the trade name Nexium ^® (Nexium ^®).

However, enteric-coated tablets such as Nexium are not suitable for the treatment of diseases requiring immediate therapeutic effect after administration, such as gastric acid-related diseases, because they are designed to dissolve and be absorbed in the intestine without immediate absorption in the stomach.

Korean Patent No. 1104349 discloses enteric coated tablets and capsules which improve the problems of stability and physical properties of omeprazole by preparing a solid dispersion formulation with magnesium oxide and povidone.

Korean Patent Publication No. 10-1996-0003605 discloses a method for preparing a solid dispersion formulation by using omeprazole as an active ingredient and adding beta-cyclodextrin and sodium hydroxide as stabilizing components. However, the invention described in the above patent has a problem of using sodium hydroxide which is harmful to the human body. The process of preparing a solid dispersion includes dissolving an active ingredient omeprazole in a solvent, and thus requires a special stabilizer such as sodium hydroxide to stabilize the omeprazole.

In order to solve these problems, Korean Patent No. 679767 discloses a method of using a buffer such as sodium bicarbonate in omeprazole.

However, the use of a large amount of sodium bicarbonate has the disadvantage of reducing the efficacy of omeprazole and causing side effects. Specifically, administration of a large amount of sodium bicarbonate may aggravate pain in critically ill patients due to swelling of the stomach, and absorption of sodium bicarbonate may cause belching, which triggers upward movement of gastric acid, causing gastroesophageal reflux. There is a possibility of worsening the disease. In addition, since patients with symptoms such as hypertension or heart failure must suppress the intake of sodium, which can cause symptoms of hypertension, it is not suitable to administer large amounts of sodium bicarbonate to patients with such symptoms. In addition, the administration of large amounts of sodium bicarbonate to patients with various complications risks metabolic alkalosis. In addition, since a buffer that changes the pH of the stomach and urine may affect drug absorption, distribution, and metabolic processes, a great deal of care should be taken in using large amounts of sodium bicarbonate together with omeprazole.

The inventors have developed a formulation comprising sodium hydrogen carbonate for the stabilization of unstable omeprazole at low pH. In order to solve the problem of using a large amount of sodium bicarbonate to increase the pH value in the stomach, while using a low content of sodium bicarbonate, the pharmaceutical composition excellent in dissolution rate and bioavailability was developed to complete the present invention.

The present invention relates to pharmaceutical compositions having improved stability, including omeprazole, enantiomers thereof or pharmaceutically acceptable salts thereof, and sodium hydrogencarbonate.

Enantiomers of omeprazole may be S-isomers or R-isomers, but isopreprazole is an S-isomer.

The "pharmaceutically acceptable salt" of the present invention may be, but is not limited to, metal salts such as sodium, potassium, calcium, magnesium, zinc, lithium, or ammonium salts, and the like. Among these, magnesium salts are preferable.

The omeprazole, its enantiomer or pharmaceutically acceptable salt thereof may be a solvate thereof, and the solvate may include hydrates such as monohydrate, dihydrate, trihydrate, etc., and may be amorphous or crystalline.

The pharmaceutical composition of the present invention may include 15 to 50 weight of sodium hydrogen carbonate, preferably 20 to 40 weight, based on 1 weight of omeprazole of omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof. .

The present invention includes omeprazole, an enantiomer or pharmaceutically acceptable salt thereof, and sodium hydrogen carbonate, wherein the omeprazole, enantiomer or pharmaceutically acceptable salt thereof comprises 20 mg or 40 mg by weight of omeprazole, It relates to a pharmaceutical composition comprising 600 to 1000 mg of sodium hydrogen.

When the sodium bicarbonate content is more than 600mg, the pH of the gastric juice can be made into a neutral environment, and the decomposition of omeprazole can be suppressed.

Preferably, the sodium bicarbonate may be 700 to 900mg, more preferably 800mg.

The present invention relates to a pharmaceutical composition comprising esomeprazole magnesium trihydrate and sodium hydrogencarbonate, wherein the esomeprazole magnesium trihydrate comprises 20 mg or 40 mg by weight of esomeprazole and comprises 800 mg sodium bicarbonate.

The composition of the present invention may be formulated into pellets, capsules, tablets (including monolayer tablets, bilayer tablets, inner core tablets), granules, and the like, but is not limited thereto.

The preparations according to the invention can be prepared according to any oral solid preparations known in the art, in particular in the preparation of granules, pellets, capsules or tablets.

The present invention relates to an improved pharmaceutical composition comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium hydrogen carbonate. The pharmaceutical composition of the present invention has improved stability, and by containing a small amount of sodium hydrogen carbonate has an excellent dissolution rate and bioavailability and the effect of reducing side effects.

Figure 1 shows the results of analysis of esomeprazole and omeprazole content according to pH.
Figure 2 shows the results of measuring the pH of the gastric juice according to the sodium bicarbonate capacity.
Figure 3 shows the dissolution test results for the formulation of Example 1 and Comparative Example 1.
Figure 4 shows the results of measuring the blood concentration change of eomeprazole for the test drug and the control drug.
Figure 5 shows the results of measuring the pH change in the stomach after the single dose and repeated administration of the test drug and the control drug, respectively.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are provided only for the purpose of illustration to help understanding of the present invention, the scope of the present invention is not limited by the following examples.

Example 1

Preparation of Esomeprazole Tablets Containing Sodium Hydrogen Carbonate

Tablets containing esomeprazole and sodium bicarbonate were prepared by the following method.

1. Primary coating

Purified water and hydroxypropyl cellulose were dissolved, and then, arginine, simethicone, purified water, esomeprazole magnesium trihydrate (22.3 mg; 20.00 mg based on emethprazole content), magnesium oxide, and talc were added to disperse the coating solution. Spherical white sugar was added to the fluidized bed granulation coater, and the coating solution was sprayed to prepare a primary pellet.

2. Secondary coating

Polyvinyl alcohol, talc, titanium oxide, glycerol monocaprylocaprate and sodium lauryl sulfate were added and dispersed in purified water to prepare a coating solution. The primary coating was placed in a fluidized bed granulator coater, and the coating solution was sprayed to prepare a secondary pellet.

3. Mixing and tableting

The secondary pellet, sodium hydrogen carbonate (800 mg), copovidone and crospovidone were added to the mixer, mixed with sodium stearyl fumarate, and the granules were prepared. The granules thus prepared were compressed.

4. 3rd coating

Polyvinyl alcohol, talc, titanium oxide, glycerol monocaprylocaprate, sodium lauryl sulfate, red iron oxide, black iron oxide, and yellow iron oxide were added to the purified water to prepare a coating solution. The tablets were added to a coater, and the coating solution was sprayed, coated, and dried to obtain a final coated tablet.

Comparative Example 1

Preparation of Esomeprazole Tablet without Sodium Hydrocarbonate

Esomeprazole tablets containing no sodium bicarbonate were prepared by the following method

1. Primary coating

After dissolving purified water and hydroxypropyl cellulose, arginine, simethicone, purified water, someprazole magnesium trihydrate, magnesium oxide, and talc were added to disperse the coating solution. Spherical white sugar was added to the fluidized bed granulation coater, and the coating solution was sprayed to prepare a primary pellet.

2. Secondary coating

Polyvinyl alcohol, talc, titanium oxide, glycerol monocaprylocaprate and sodium lauryl sulfate were added and dispersed in purified water to prepare a coating solution. The primary coating was placed in a fluidized bed granulator coater, and the coating solution was sprayed to prepare a secondary pellet.

3. Mixing and tableting

The secondary pellet, lactose, microcrystalline cellulose, copovidone and crospovidone were mixed and mixed, and then stearic sodium fumarate was added to make a granule. The granules were compressed.

4. 3rd coating

Polyvinyl alcohol, talc, titanium oxide, glycerol monocaprylocaprate, sodium lauryl sulfate, red iron oxide, black iron oxide, and yellow iron oxide were added to the purified water to prepare a coating solution. The tablets were added to a coater, and the coating solution was sprayed, coated, and dried to obtain a final coated tablet.

[Test Example 1]

Stability Test of Esomeprazole and Omeprazole with pH

To 100 mL of buffer solution, 20 mL / mL of omeprazole and 2 mL of omeprazole solution were added, and the contents were analyzed according to pH.

<Method of analysis>

A) Detector: ultraviolet visible absorption photometer (wavelength: 280 nm)

B) Column: Inertsil C8-3 (4.6 × 150 mm, 5 ㎛) or equivalent column

C) Injection volume: 20 μl

D) flow rate: 1.5 mL / min

E) Column temperature: Constant temperature around 40 ℃

F) Sample temperature: constant temperature around 10 ℃

G) Analysis time: 6 minutes

H) Mobile phase: Mixed solution of pH 7.6 buffer and acetonitrile (65: 35)

The pH 7.6 buffer solution was prepared by adding 0.725 g of sodium hydrogen phosphate monohydrate (NaH 2 PO 4 H 2 O) and 4.472 g of disodium hydrogen phosphate anhydride (Na 2 HPO 4) in a 1 L volumetric flask, dissolving it in purified water, and taking 250 mL of the marked solution. Placed in a flask and labeled with purified water and adjusted to pH 7.6 with phosphoric acid

The analysis results are shown in Table 1 and FIG. 1.

5 minutes 10 minutes 15 minutes 30 minutes 45 minutes 60 minutes 120 minutes pH
4.0 S-omeprazole 64.1 31.0 15.9 6.9 1.7 0.9 0.1 Omeprazole 57.2 29.4 15.3 6.7 1.6 0.8 0.1 pH
6.0 S-omeprazole 74.4 72.8 71.0 68.9 66.3 63.6 54.9 Omeprazole 74.9 74.2 71.7 69.6 65.4 64.1 55.1 pH
6.8 S-omeprazole 95.6 90.8 90.5 89.7 88.9 88.3 86.2 Omeprazole 91.5 90.5 89.9 89.8 88.8 88.3 85.5 pH
7.0 S-omeprazole 99.6 99.0 99.3 98.9 98.7 98.1 96.8 Omeprazole 100.5 99.0 98.9 98.2 97.9 97.5 95.8 pH
7.3 S-omeprazole 100.1 100.1 100.0 100.0 100.0 100.0 99.90 Omeprazole 99.8 100.0 99.9 99.8 99.8 99.8 99.86 pH
7.5 S-omeprazole 99.4 99.3 99.2 99.1 99.3 99.1 98.2 Omeprazole 100.5 99.7 99.7 99.4 99.2 98.9 98.2 pH
8.0 S-omeprazole - - 101.1 100.9 100.7 100.7 100.0 Omeprazole - - 99.7 99.6 99.5 99.5 98.6

As shown in Table 1, it was confirmed that the esomeprazole and omeprazole exhibit a minimum of 2 hours stability when the pH is more than 7.0.

[Test Example 2]

PH Verification Test of Artificial Gastric Fluid According to Sodium Hydrogen Carbonate Capacity

In order to set the sodium bicarbonate content, drug release conditions and gastric juice conditions were set as follows. Specifically, 1) the amount of gastric juice on an empty stomach is generally 20 to 50 mL, 2) the amount of gastric juice secreted is about 2 L / day (about 83 mL / hr), and 3) the total amount of gastric juice reacted with the drug (formulation) is Assuming about 200 mL, 4) the drug is taken with water, and the amount of water is 200 mL.

Therefore, the pH was measured while changing the sodium bicarbonate capacity in a solution (37 ° C.) containing 200 mL of artificial gastric juice and 200 mL of purified water, and the measurement results are shown in Table 2 and FIG. 2.

Sodium bicarbonate
(mg) 500 600 700 800 900 1,000 1,100 1,200 1,300 pH 5.77 6.51 7.30 7.30 7.31 7.37 7.38 7.38 7.40

As shown in Table 2, the pH value was increased as the capacity of sodium bicarbonate was increased, and it was confirmed that the pH was hardly changed at 1,000 mg or more of sodium bicarbonate. In addition, it was confirmed that the amount of sodium hydrogen carbonate that can neutralize 200 mL of artificial gastric juice to have a neutral pH is at least 600 mg.

[Test Example 3]

Dissolution test of preparations with or without sodium hydrogencarbonate

For the formulation of Example 1 and Comparative Example 1, dissolution test was carried out, dissolution test and analysis conditions are as follows.

<Elution test condition>

1) Elution method: Korea Pharmacopoeia 3rd law (Flow Through Cell method)

2) Eluent: pH 1.2 → pH 4.0

3) Elution temperature: 37 ± 0.5 ℃

4) Flow rate: 2mL / min

5) Test time: pH 1.2 (15 minutes) → pH 4.0 (15 minutes)

<Analysis condition>

1) Detector: ultraviolet absorbance photometer (wavelength: 302 nm)

2) Column: Capcell Pak C18 (4.6 × 150 mm, 5 μm) or equivalent column

3) Injection amount: 20 μL

4) Flow rate: 1.0 mL / min

5) Column temperature: Constant temperature around 30 ℃

6) Sample temperature: Constant temperature around 10 ℃

7) Mobile phase: a mixture of acetonitrile, pH 7.3 buffer and water (350: 500: 150)

pH 7.3 buffer is a solution of 10.5 mL of 1 mol / L sodium dihydrogen phosphate solution and 60 mL of 0.5 mol / L sodium dihydrogen phosphate solution in a 1 L volumetric flask and labeled with purified water.

The dissolution test results are shown in Table 3 and FIG. 3.

Dissolution rate Example 1
(Test area) Example 1 *
Concentration (ng / mL) Comparative Example 1
(Test area) Comparative Example 1 *
Concentration (ng / mL) 5 minutes 4,462,741 798.50 22,929 4.10 10 minutes 3,696,359 661.38 8,566 1.53 15 minutes 3,074,658 550.14 4,585 0.82 20 minutes 1,954,877 349.78 2,185 0.39 25 minutes 1,189,882 212.90 835 0.15 30 minutes 786,910 140.80 9,793 1.75

* The density | concentration of Example 1 and the comparative example 1 is the value which converted the sample liquid area value into the standard liquid area value (about 1,400,000).

As shown in Table 3, the dissolution rate of Comparative Example 1 containing no sodium hydrogen carbonate is very low, it can be confirmed that almost does not elute. On the other hand, the dissolution rate of Example 1 containing sodium hydrogen carbonate showed an excellent dissolution rate compared to the dissolution rate of Comparative Example 1, it was confirmed that the highest dissolution rate after 5 minutes of administration eluted quickly.

[Test Example 4]

Blood Levels of Someprazole

Changes in serum concentrations of esomeprazole in blood over time after repeated administration of the test drug (complex tablets prepared according to the preparation method of Example 1) and the control drug (commercially available Nexium tablet 20mg) once daily for 7 days. And AUC values are shown in Table 4 and FIG. 4.

AUC (hng / mL) Reference Test drug 2578.09 2802.25

As shown in Table 4 above, the test drug showed better AUC values than the control drug.

In addition, as shown in FIG. 4, the test drug was eluted and absorbed immediately after administration as compared to the control drug which is an enteric preparation, and showed high blood concentration. Since it is important to have an immediate therapeutic effect after administration due to the nature of the disease, it can be seen that the test drug has a superior effect than the reference drug.

It can be seen that the test drug shows a higher blood concentration up to 2 hours compared to the control drug, and shows a similar blood concentration after 2 hours, thereby having an excellent bioavailability.

[Test Example 5]

PH change in the stomach

For the test drug (complex tablet prepared according to the preparation method of Example 1) and the control drug (commercial Nexium tablet 20mg), the pH change in the stomach was measured after a single dose and 7 days repeated administration. The time to maintain pH≤4 in the gastric pH observed for 24 hours after administration was measured and the results are shown in Table 5 and FIG. 5.

Gastric acid loss rate (%) Test drug Reference Baseline 80% 80% Single dose 43.20% 44.49% Repeated administration 30.07% 29.84%

When the reference and test drugs were administered, the time for maintaining the gastric pH of 4 or less in a single dose compared to the baseline was reduced from about 80% to 44.49% and 43.20%, respectively. When repeated administration, the control and test drugs were 29.84% and 30.07%, respectively. Therefore, it was confirmed that the time for maintaining the gastric pH of 4 or less was similar for the baseline, single and repeated doses.

As a result, the formulations of the present invention exhibit superior bioavailability and therapeutic effects of gastric acid-related diseases due to the higher initial drug release, absorption, and blood concentration compared to enteric formulations.

Claims (8)

Omeprazole, enantiomers thereof or pharmaceutically acceptable salts thereof; And sodium hydrogen carbonate,
A pharmaceutical composition, characterized in that the weight of sodium hydrogen carbonate is 15 to 50% by weight based on 1 weight of omeprazole of the omeprazole, its enantiomer or pharmaceutically acceptable salt thereof.
The pharmaceutical composition according to claim 1, wherein the sodium hydrogen carbonate has a weight of 20 to 40 weight.
The pharmaceutical composition of claim 1, wherein the omeprazole, its enantiomer or pharmaceutically acceptable salt thereof is esomeprazole.
The pharmaceutical composition according to claim 1, wherein the omeprazole, its enantiomer or pharmaceutically acceptable salt thereof is esomeprazole magnesium salt.
Omeprazole, enantiomers thereof or pharmaceutically acceptable salts thereof; And sodium hydrogen carbonate,
The omeprazole, its enantiomer or pharmaceutically acceptable salt thereof comprises 20 mg or 40 mg by weight of omeprazole and 600 to 1000 mg of sodium bicarbonate.
6. The pharmaceutical composition of claim 5 comprising 700 to 900 mg of sodium hydrogen carbonate.
The pharmaceutical composition of claim 6 comprising 800 mg of sodium hydrogen carbonate.
Esomeprazole magnesium trihydrate and sodium bicarbonate,
The esomeprazole magnesium trihydrate is 20 mg or 40 mg based on the weight of esomeprazole, and
A pharmaceutical composition comprising sodium hydrogen carbonate 800 mg.

Images